Q2 2026 Vivos Therapeutics Inc Earnings Call Transcript
Key Points
- Revenue increased 35% year-over-year to $5.2 million in Q2 2026, driven by a $1.9 million rise in service revenue from the Sleep Center of Nevada (SCN) acquisition.
- Gross margin improved to 57% in Q2 2026, up from 53% in the prior-year period, reflecting higher revenue and controlled cost growth.
- SCN patient volume growth is driving a 3-4x increase in referrals to SAMC treatment centers, expected to boost Q3 2026 financial results.
- Remote patient monitoring for CPAP patients targets 5,000-7,500 enrollments from a legacy base of 16,000, with estimated net revenue of $40-$50 per patient per night.
- Expansion of the Henderson, Nevada facility has more than doubled production capacity to over $10 million annually, supporting future growth.
- New initiatives, including a DME-based CPAP program and insomnia/EEG testing, are projected to add recurring revenue streams, with the CPAP program potentially generating $150,000-$250,000 per month in contribution margin.
- Management sees a clear path to positive cash flow by late 2026 or early 2027, with significant positive EBITDA expected in fiscal 2027.
- The company has a going concern risk, with only $1.8 million in cash as of June 30, 2026, insufficient to fund operations for the next 12 months.
- Net losses widened to $5.5 million in Q2 2026 and $13.3 million for the first half, with an accumulated deficit of $138 million.
- Product revenue from oral appliance sales decreased 28% in Q2 2026 due to a strategic pivot away from VIPs, impacting overall revenue mix.
- The company is not in compliance with NASDAQ's minimum stockholders' equity requirement, facing potential delisting proceedings.
- General and administrative expenses rose 11% in Q2 2026, driven by higher salaries, rent, and integration costs from the SCN acquisition.
- Cash used in operating activities increased to $9.2 million in the first half of 2026, up from $7.3 million in the prior-year period.
- The company relies on external financing, having raised only $0.5 million through ATM sales in the first half, with $2.3 million remaining available.
Good day, everyone, and welcome to the Vivos Therapeutics second quarter 2026 conference call. (Operator Instructions)
This conference call is being recorded, and a replay of today's call will be available on the Investor Relations section of Vivos website and will remain posted there for the next 30 days.
I would now like to hand the conference over to Brad Amman, Principal Accounting Officer and former CFO for introductions and the reading of the safe harbor statement. Please go ahead.
Thank you, Ludy. Hello, everyone, and welcome to our conference call. A copy of our earnings press release is available on the Investor Relations section of our website at www.vivos.com.
With me on the call today is Kirk Huntsman, Vivos' Chairman and Chief Executive Officer; and Roman Franklin, Vivos' Chief Financial Officer and Principal Financial Officer.
Today, we will review the financial results of the second
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
